StockMarketsReview.com -- A U.S. Food and Drug Administration panel on Friday unanimously opposed Germany's Boehringer Ingelheim Pharmaceuticals, Inc.'s new drug application for Flibanserin 100 mg tablet for the proposed indication for treatment of hypo-active sexual desire disorder or HSDD, in premenopausal women. The panel voted 11-to-0 against the drugs approval.
